Experience

Kestrel Therapeutics
• United States
• Biotechnology
• 1 - 100 Employee
• Senior Director of Biophysics and Structural Biology

  • Jun 2023 - Present

Foghorn Therapeutics Inc.
• United States
• Biotechnology Research
• 100 - 200 Employee
• Senior Director of High Throughput Screening

  • Nov 2022 - Mar 2023


H3 Biomedicine

• United States
• Pharmaceutical Manufacturing
• 1 - 100 Employee

• • Jan 2019 - Sep 2022

  + Led department of ~14 incredible scientists supporting multiple drug discovery programs with protein science, biochemistry/physics, proteomics, structural biology, compound management and automation. Collaborated closely with biology and chemistry department heads to deliver across portfolio. + Contributed to 3 programs that were tested in Phase I/II clinical trials. (H3B-6527 for FGFR4, H3B-6545 for ERa, and H3B-8800 for mRNA splicing)+ Delivered first in class allosteric lead compounds including disclosed: CPS1, DNMT3a, and WRN.+ Oversaw budgets for capex to implement strategic upgrades of internal screening libraries and automation lab. Managed budgets and deliverables from numerous outsourcing CRO partners. CPS1: https://www.cell.com/cell-chemical-biology/fulltext/S2451-9456(20)30034-9https://pubs.acs.org/doi/10.1021/acsmedchemlett.0c00145DNMT3A: https://www.jbc.org/article/S0021-9258(20)30537-8/fulltextERa (H3B-6545): https://aacrjournals.org/mct/article/21/6/890/699203FGFR: https://pubs.acs.org/doi/10.1021/acsmedchemlett.0c00517PPARg: *https://www.jbc.org/article/S0021-9258(22)00982-6/fulltextSF3B1 (spliceosome)https://www.nature.com/articles/s41467-023-36489-xhttps://www.nature.com/articles/s41467-021-24741-1*https://link.springer.com/chapter/10.1007/978-3-030-58971-4_12*corresponding author Show less

• • Nov 2015 - Dec 2018

  + Lab head leading a team of two scientists and a postdoc supporting multiple drug discovery programs with protein science, biochemistry/physics, and structural biology. + Led the HTS screening campaign on the transcription factor / nuclear hormone receptor PPARg. Discovered lead series that resulted in eventual candidate selection for a first in class inhibitor.+ Developed in house ADC production capabilities to accelerate timelines to candidate selection. + Initiated key external collaborations (Vlad Pena at ICR London and Yigong Shi at Westlake U.) to support structural biology on splicing program. Led efforts to determine the MOA of splicing inhibitors.ERa (H3B-5942): https://aacrjournals.org/cancerdiscovery/article/8/9/1176/10351FGFR4 (H3B-6527): https://aacrjournals.org/cancerres/article/77/24/6999/624836PPARg: https://www.nature.com/articles/s41467-017-00147-wSF3B1 (spliceosome):https://www.cell.com/molecular-cell/fulltext/S1097-2765(18)30214-4*https://genesdev.cshlp.org/content/32/3-4/309*https://www.nature.com/articles/ncomms15522*corresponding author Show less

• • Sep 2012 - Nov 2015

  + Lab head leading two scientists. Built protein science, biophysics, and structural biology platforms. Delivered dozens of crystal structures to enable structure based drug design. Collaborated with numerous project teams including disclosed: ERa, FGFR4, PPARg, SF3B1 (spliceosome), etc.



AstraZeneca

• United Kingdom
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Senior Scientist

  • Jan 2008 - Sep 2012

  + Head of the protein sciences platform in the oncology therapeutic area (2010-2012). Led team of 3 scientists. Delivered proteins for a range of applications (screening and structural biology). Validated hits from screening campaigns using orthogonal biophysical methods. + Structural biologist supporting oncology and infection (2008-2009). Solved numerous structures to support structure based drug design. + Collaborated with numerous project teams including disclosed: ALK, BCL2, CK2, EZH2, FGFR, GLMU, IAP, JAK1, KIFC1, MCL1, PIM1, SMYD2, TAK1-TAB, TANK1, TBK1, TMK. SMYD2: https://www.cell.com/structure/fulltext/S0969-2126(11)00234-6 GLMU: https://portlandpress.com/biochemj/article-abstract/446/3/405/46072 Show less



Harvard Medical School

• United States
• Higher Education
• 700 & Above Employee

• Leukemia and Lymphoma Society Fellow & Jane Coffin Childs Fellow

  • Jul 2003 - Dec 2007

  Postdoctoral Fellow in Steve Harrison's lab. Worked on proteins in the mitotic spindle checkpoint (Bub1/Bub3, Aurora B, etc). Initiated collaborations and determined additional structures (BluB & IroE) with Graham Walker (MIT) and Chris Walsh (Harvard). Bub3: https://www.pnas.org/doi/full/10.1073/pnas.0610358104 IroE: https://pubs.acs.org/doi/10.1021/bi060950i BluB: https://www.nature.com/articles/nature05611 Postdoctoral Fellow in Steve Harrison's lab. Worked on proteins in the mitotic spindle checkpoint (Bub1/Bub3, Aurora B, etc). Initiated collaborations and determined additional structures (BluB & IroE) with Graham Walker (MIT) and Chris Walsh (Harvard). Bub3: https://www.pnas.org/doi/full/10.1073/pnas.0610358104 IroE: https://pubs.acs.org/doi/10.1021/bi060950i BluB: https://www.nature.com/articles/nature05611